Form 8-K - Current report:
SEC Accession No. 0001104659-25-022371
Filing Date
2025-03-11
Accepted
2025-03-11 06:30:22
Documents
13
Period of Report
2025-03-10
Items
Item 1.01: Entry into a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm258743d1_8k.htm   iXBRL 8-K 26658
  Complete submission text file 0001104659-25-022371.txt   202803

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA apge-20250310.xsd EX-101.SCH 3045
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE apge-20250310_lab.xml EX-101.LAB 34240
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE apge-20250310_pre.xml EX-101.PRE 22379
15 EXTRACTED XBRL INSTANCE DOCUMENT tm258743d1_8k_htm.xml XML 3815
Mailing Address 221 CRESCENT ST. BUILDING 17, SUITE 102B WALTHAM MA 02453
Business Address 221 CRESCENT ST. BUILDING 17, SUITE 102B WALTHAM MA 02453 650-394-5230
Apogee Therapeutics, Inc. (Filer) CIK: 0001974640 (see all company filings)

EIN.: 934958665 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41740 | Film No.: 25725782
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)